MedTrace Logo

A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus

NCT00642538 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-06-14

No results posted yet for this study

Summary

20 eligible subjects will be enrolled into the treatment phase of the trial.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

MKC253 Inhalation Powder

Inhalation Powder, prandial

DRUG

Technosphere Inhalation Powder

Inhalation Powder, prandial

DRUG

subcutaneous injection

10µg Exenatide, prandial

Sponsors & Collaborators

  • Mannkind Corporation

    lead INDUSTRY

Principal Investigators

  • Anders Boss · Mannkind Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00642538 on ClinicalTrials.gov